CRISPR Therapeutics AG

NASDAQ Global Market
Back to all articles
Somewhat Bullish +45

CRISPR Therapeutics' (CRSP) Market Outperform Rating Reaffirmed at ...

📈 Citizens Jmp restated its rating to market outperform with an $80 price target on CRSP.

📊 Truist Financial upgraded the stock to strong-buy while Piper Sandler raised its target to $110.

💰 Q1 revenue reached $1.46 million, though the company posted a loss of $1.28 per share.

🔮 Analysts predict full-year earnings of -$4.89 per share for the current fiscal year.

🏦 ARK Investment Management LLC increased its stake by 7.5% to own over $551 million in shares.

📉 Insider Naimish Patel sold 3,786 shares worth $210,577 to cover tax withholding obligations.

🧬 The company focuses on ex vivo gene-editing therapies for sickle cell disease and thalassemia.

🤝 CRISPR Therapeutics collaborates with Vertex Pharmaceuticals on its lead CTX001 program.

📊 Institutional ownership stands at 69.20% following recent additions by State Street and GSK.

Bullish Signals
  • Citizens Jmp reaffirmed a market outperform rating with an $80 price target, signaling continued institutional confidence in the company's long-term prospects.
  • Truist Financial upgraded CRSP to a strong-buy rating, while Piper Sandler raised its price target from $105 to $110, indicating growing analyst optimism.
  • Major institutional investors including ARK Investment Management LLC, State Street Corp, and GSK plc have recently increased their positions, with ARK adding over $735 million in value.
  • The company maintains a strong pipeline of ex vivo gene-editing therapies targeting serious diseases like sickle cell disease and transfusion-dependent beta-thalassemia.
Risk Factors
  • Analysts forecast a full-year loss of $4.89 per share for the current fiscal year, highlighting the company's continued cash burn before commercialization milestones.
  • Insider Naimish Patel sold 3,786 shares worth $210,577 to cover tax withholding obligations, reducing his direct ownership by 16.36%.
Full Analysis
Citizens Jmp reaffirmed its market outperform rating on CRISPR Therapeutics (CRSP) with a $80 price target, joining a chorus of recent analyst activity including Truist Financial's strong-buy upgrade and Piper Sandler raising its target to $110. While some analysts like Sanford C. Bernstein maintained hold ratings, the aggregate sentiment remains moderately bullish with an average target price of $67.78. The company recently reported Q1 earnings of $1.46 million in revenue against a loss of $1.28 per share, resulting in negative net margins and return on equity. Analysts currently forecast a full-year loss of $4.89 per share for the current fiscal year, reflecting the high-burn nature of its gene-editing R&D pipeline focused on ex vivo therapies. Institutional ownership remains robust at 69.20%, with significant recent accumulation from major funds including ARK Investment Management LLC, State Street Corp, and GSK plc. Notably, insider Naimish Patel sold shares totaling $210,577 to cover tax withholding obligations related to equity vesting, a transaction that reduced his direct ownership by 16.36%.